Alterity Therapeutics Ltd has released a press release.
Alterity presents initial Phase 1 clinical trial data at AAN
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
In the deck
Earlier from Alterity Therapeutics
- Prana receives A$3.3 million R&D Tax Incentive Refund
- Orphan Designation for PBT434 for treatment of MSA
- Life Bioscience LLC leads strategic investment upto A$44.5M
- New data show potential for PBT434 to treat MSA
- Annual Report to shareholders
Later from Alterity Therapeutics
- Successful Completion of Phase 1 Clinical Trial
- Appendix 4E & Annual Report 2019
- Lead drug candidate receives positive opinion from EMA
- Chairmans Address to Shareholders
- AGM Presentation 2019
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics